ALPAPharmaceuticals
Alpa Laboratories Ltd — Cash Flow Statement
₹46.46
-9.93%
Alpa Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -4.32 Cr | -2.74 Cr | 7.78 Cr | 7.75 Cr | — |
| Capital Expenditure | -11.38 Cr | -6.39 Cr | -1.13 Cr | -2.19 Cr | — |
| End Cash Position | 3.59 Cr | 3.11 Cr | 8.81 Cr | 1.58 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 1000.00 | — | — | -1000.00 | -0.01 Cr |
| Beginning Cash Position | 3.11 Cr | 10.21 Cr | 1.58 Cr | 1.80 Cr | — |
| Changes In Cash | 0.48 Cr | -7.10 Cr | 7.24 Cr | -0.23 Cr | — |
| Financing Cash Flow | -5.48 Cr | 2.58 Cr | -3.79 Cr | 5.44 Cr | — |
| Interest Paid Cff | -0.23 Cr | -0.36 Cr | -0.22 Cr | -0.22 Cr | — |
| Net Issuance Payments Of Debt | -5.25 Cr | 3.72 Cr | -3.57 Cr | 5.66 Cr | — |
| Net Short Term Debt Issuance | -5.25 Cr | 3.72 Cr | -0.03 Cr | 5.85 Cr | — |
| Investing Cash Flow | -1.10 Cr | -13.34 Cr | 2.13 Cr | -15.61 Cr | — |
| Interest Received Cfi | 2.04 Cr | 2.32 Cr | 1.04 Cr | 1.46 Cr | — |
| Dividends Received Cfi | 0.37 Cr | 0.25 Cr | 0.19 Cr | 0.07 Cr | — |
| Net Investment Purchase And Sale | -3.39 Cr | -9.51 Cr | -0.03 Cr | -19.18 Cr | — |
| Purchase Of Investment | -3.39 Cr | -9.51 Cr | -0.03 Cr | -19.18 Cr | — |
| Net Business Purchase And Sale | 11.26 Cr | 0.00 | -0.50 Cr | 4.23 Cr | — |
| Sale Of Business | 11.26 Cr | — | — | 4.23 Cr | 0.00 |
| Net PPE Purchase And Sale | -11.38 Cr | -6.39 Cr | -1.13 Cr | -2.19 Cr | — |
| Operating Cash Flow | 7.06 Cr | 3.65 Cr | 8.90 Cr | 9.94 Cr | — |
| Taxes Refund Paid | -4.07 Cr | -3.64 Cr | -3.60 Cr | -3.12 Cr | — |
| Change In Working Capital | 11.67 Cr | -4.06 Cr | -0.80 Cr | 1.45 Cr | — |
| Change In Payable | 20.41 Cr | -3.71 Cr | 1.98 Cr | -8.20 Cr | — |
| Change In Inventory | -3.97 Cr | -1.02 Cr | 2.82 Cr | 1.10 Cr | — |
| Change In Receivables | -8.21 Cr | 2.00 Cr | -6.64 Cr | 7.59 Cr | — |
| Other Non Cash Items | -12.46 Cr | -1.48 Cr | -0.82 Cr | -1.24 Cr | — |
| Depreciation And Amortization | 2.20 Cr | 1.95 Cr | 1.33 Cr | 1.66 Cr | — |
| Depreciation | 2.20 Cr | 1.95 Cr | 1.33 Cr | 1.66 Cr | — |
| Gain Loss On Investment Securities | -16.83 Cr | -10.29 Cr | -3.49 Cr | -8.90 Cr | — |
| Net Income From Continuing Operations | 25.82 Cr | 20.76 Cr | 15.68 Cr | 19.56 Cr | — |
| Issuance Of Debt | — | 3.72 Cr | — | — | 0.45 Cr |
| Net Other Financing Charges | — | -0.78 Cr | 1000.00 | -1000.00 | 1000.00 |
| Short Term Debt Issuance | — | 3.72 Cr | — | — | — |
| Net Long Term Debt Issuance | — | -0.78 Cr | -3.54 Cr | 5.66 Cr | 0.27 Cr |
| Net Other Investing Changes | — | -1000.00 | 2.55 Cr | — | 0.01 Cr |
| Purchase Of Business | — | 0.00 | -0.50 Cr | -0.01 Cr | 0.00 |
| Repayment Of Debt | — | — | -0.03 Cr | — | -0.18 Cr |
| Short Term Debt Payments | — | — | -0.03 Cr | — | — |
| Purchase Of PPE | — | — | -1.13 Cr | -2.19 Cr | -3.22 Cr |
| Gain Loss On Sale Of PPE | — | — | 0.00 | 0.00 | 0.06 Cr |
| Sale Of PPE | — | — | — | 0.00 | 0.37 Cr |
| Long Term Debt Payments | — | — | — | — | -0.18 Cr |
| Long Term Debt Issuance | — | — | — | — | 0.45 Cr |
| Sale Of Investment | — | — | — | — | 7.91 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Alpa Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.